Page 8 - Genentech News Today

Filed Pursuant to Rule 424 Registration No. 333-277758 PROSPECTUS SUPPLEMENT Up to $39,966,424...

MAINZ, Germany, May 21, 2024 - BioNTech SE(Nasdaq: BNTX, "BioNTech" or "the Company") will present clinical trial data for selected programs from the Company's diversified immuno-oncology pipeline at the

Investegate announcements from BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024

No magic bullet is in sight yet, but three vaccines for particular skin and lung cancer types have advanced to the last phase of clinical trials.

Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced updates to its 2nd Annual Spinal Cord Injury Investor Symposium ("2nd SCIIS"). The 2nd SCIIS aims...

As value-based health care models become more widespread, these types of interventions will be important to demonstrate the value of pharmacist-embedded HSSPs.

Currently available flu medications only target the virus after it has already established an infection, but what if a drug could prevent infection in the first place? Now, scientists at Scripps Research and the Albert Einstein College of Medicine have designed drug-like molecules to do just that, by thwarting the first stage of influenza infection.

NEW YORK, May 21, 2024 /PRNewswire/ -- Surgical teams at NYU Langone Health performed the worlds first genetically modified pig kidney transpl

COVID-19 antibodies are significantly reduced by 6 months post-vaccination among patients with immune-mediated inflammatory diseases, according to data published in The Journal of Rheumatology.However, individuals with diseases such as rheumatoid arthritis and systemic lupus erythematosus continued to see positive impacts to immunogenicity with fourth and fifth doses of COVID-19 vaccines, the

Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target ...